Related Experiment Video
Updated: May 20, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Longitudinal model-based meta-analysis in rheumatoid arthritis: an application toward model-based drug development
I Demin1, B Hamrén, O Luttringer
1Department of Modeling and Simulation, Novartis Pharma AG, Basel, Switzerland. ivan.demin@novartis.com
Clinical Pharmacology and Therapeutics
|July 5, 2012
Summary
This study analyzed rheumatoid arthritis (RA) drug data, finding canakinumab unlikely to outperform current treatments. This supports informed decisions in RA drug development.
Area of Science:
- Rheumatology
- Clinical Pharmacology
- Biostatistics
Background:
- Longitudinal data on rheumatoid arthritis (RA) drug efficacy exists.
- This data can optimize new RA drug clinical development.
- Quantifying the time course of American College of Rheumatology (ACR) scores is crucial.
Purpose of the Study:
- To model the time course of ACR20 scores for approved RA drugs.
- To assess canakinumab's potential efficacy against existing RA treatments.
- To inform clinical development decisions for new RA compounds.
Main Methods:
- A longitudinal model-based meta-analysis was performed.
- Data from 37 Phase II-III studies (13,474 patients) were integrated.
- The analysis focused on the ACR20 score.
Main Results:
- Canakinumab, at tested doses, showed a low probability of exceeding current RA treatments.
- The model provides a quantitative assessment of drug efficacy over time.
- This analysis supports evidence-based decision-making in drug development.
Conclusions:
- The study supports the decision to halt canakinumab's RA development.
- The developed framework can guide decisions for other RA drug candidates.
- Model-based meta-analysis enhances clinical development strategy for RA therapies.
Related Concept Videos
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:29Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
01:14Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
01:09Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).